Boston Scientific has signed a definitive agreement to acquire Xlumena, a device company that focuses on the development, manufacture and sale of minimally invasive devices for endoscopic ultrasound.
Xlumena's portfolio includes the AXIOS and HOT AXIOS Stent and Delivery Systems. The AXIOS system has FDA clearance and a CE Mark. The next-generation HOT AXIOIS system has a CE Mark.
Boston Scientific will pay $62.5 million upfront and an additional $12.5 million when the HOT AXIOS system receives FDA clearance.
"We believe the acquisition of Xlumena and their minimally-invasive products combined with the Boston Scientific broad product portfolio demonstrates our commitment to advancing the field of interventional EUS therapeutics," said David Pierce, senior vice president and president of endoscopy at Boston Scientific.